<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03173417</url>
  </required_header>
  <id_info>
    <org_study_id>YMCART201702</org_study_id>
    <nct_id>NCT03173417</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Evaluation of IM19 CAR-T Cells (IM19CAR-T)</brief_title>
  <official_title>Safety and Efficacy Evaluation of IM19 CAR-T Cells On CD19+ Refractory or Relapsed B-ALL Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Immunochina Medical Science &amp; Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Immunochina Medical Science &amp; Technology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of the Safety and Feasibility of Administering T Cells Expressing an Anti-CD19&#xD;
      Chimeric Antigen Receptor to Patients With CD19+ B-cell leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Assessment of the Safety and Feasibility of Administering T Cells Expressing an Anti-CD19&#xD;
      Chimeric Antigen Receptor to Patients With CD19+ B-cell leukemia and determine the best&#xD;
      dosage.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 23, 2017</start_date>
  <completion_date type="Actual">May 1, 2019</completion_date>
  <primary_completion_date type="Actual">May 1, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of study related adverse events</measure>
    <time_frame>2 years</time_frame>
    <description>defined as &gt;= Grade 3 signs/symptoms, laboratory toxicities, and clinical events) that are possibly, likely, or definitely related to study treatment Adverse events assessed according to NCI-CTCAE v4.0 criteria 2.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>2 years</time_frame>
    <description>An objective response is defined as: (1) a morphologic complete response (CR) or (2) a complete response with incomplete recovery of counts (CRi) (based on NCCN guidelines (National Comprehensive Cancer Network (NCCN), 2014) or (3) a negative minimal residual disease assessed by flow cytometry</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">177</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>IM19 CART</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will be treated with fludarabine and cyclophosphamide for 3 days,then,CAR-T cells expressing CD19 CAR will be infused 24-96 hours later.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IM19 CAR-T</intervention_name>
    <description>T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor</description>
    <arm_group_label>IM19 CART</arm_group_label>
    <other_name>IM19</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine and cyclophosphamide</intervention_name>
    <description>Two days before cell infusion,all patients will be treated with fludarabine and cyclophosphamide for 3 days</description>
    <arm_group_label>IM19 CART</arm_group_label>
    <other_name>FC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with CD19+ Refractory or Relapsed B-ALL（At least 2 prior combination&#xD;
             chemotherapy regimens）&#xD;
&#xD;
          2. To be aged 3 to 75 years&#xD;
&#xD;
          3. Blast in blood ≤ 30%&#xD;
&#xD;
          4. ECOG score ≤2&#xD;
&#xD;
          5. Women of childbearing potential must have a urine pregnancy test taken and proven&#xD;
             negative prior to the treatment. All patients agree to use reliable methods of&#xD;
             contraception during the trial period and until follow-up for the last time.&#xD;
&#xD;
          6. Voluntary participation in the clinical trials and sign the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Intracranial hypertension or unconsciousness&#xD;
&#xD;
          2. Respiratory failure&#xD;
&#xD;
          3. CD19 negative&#xD;
&#xD;
          4. Disseminated intravascular coagulation&#xD;
&#xD;
          5. ALT /AST&gt;3 x normal value; Creatinine&gt; 1.5 x normal value; Bilirubin &gt;2.0 x normal&#xD;
             value&#xD;
&#xD;
          6. Hematosepsis or Uncontrolled active infection&#xD;
&#xD;
          7. Uncontrolled diabetes&#xD;
&#xD;
          8. Abalienation;&#xD;
&#xD;
          9. WHO Sscore &gt;3&#xD;
&#xD;
         10. Patients in pregnancy or breast-feeding period&#xD;
&#xD;
         11. Previously treatment with any gene therapy products&#xD;
&#xD;
         12. Any uncontrolled medical disorders that the researchers consider are not eligible to&#xD;
             participate the clinical trial&#xD;
&#xD;
         13. Any situation that would increase dangerousness of subjects or disturb the outcome of&#xD;
             the clinical study according to the researcher's evaluation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>PEIHUA LU, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hebei Yanda Ludaopei Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hebei Yanda Ludaopei Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 30, 2017</study_first_submitted>
  <study_first_submitted_qc>May 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2017</study_first_posted>
  <last_update_submitted>May 17, 2019</last_update_submitted>
  <last_update_submitted_qc>May 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

